Tyra Biosciences Inc
NASDAQ:TYRA

  • LAST PRICE
    15.3600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    14.5000/ 1
  • Ask / Lots
    16.9500/ 1
  • Open / Previous Close
    --- / 15.3600
  • Day Range
    ---
  • 52 Week Range
    10.6004
    29.6000
  • Volume
    2

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
TYRA
Tyra Biosciences Inc
777.3M
-9.6x
---
KURA
Kura Oncology Inc
782.3M
-4.3x
---
AVXL
Anavex Life Sciences Corp
764.9M
-18.0x
---
REPL
Replimune Group Inc
755.0M
-3.6x
---
AUTL
Autolus Therapeutics PLC
755.7M
-2.4x
---
ERAS
Erasca Inc
734.5M
-3.1x
---
As of 2024-11-22

Company Information

Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.

Contact Information

Headquarters
2656 State StreetCARLSBAD, CA, United States 92008
Phone
619-728-4760
Fax
302-655-5049

Executives

Non-Executive Chairman of the Board
Robert More
President, Chief Executive Officer, Treasurer, Director
Todd Harris
Chief Financial Officer
Alan Fuhrman
Chief Operating Officer
Daniel Bensen
Chief Medical Officer
Douglas Warner

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$777.3M
Revenue (TTM)
$0.00
Shares Outstanding
50.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.61
Book Value
$4.75
P/E Ratio
-9.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.